Phase 2a study of the safety, tolerability, and pharmacokinetics of topically administered PRN473 (SAR444727) in patients with mild to moderate atopic dermatitis

Trial Identifier: ACT17131
Sponsor: Principia Biopharma, a Sanofi Company
Start Date: August 2021
Primary Completion Date: December 2022
Study Completion Date: December 2022
Condition: Eczema

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, Ontario Hamilton, Ontario, Canada, L8L 3C3
Canada, Ontario London, Ontario, Canada, N6H 5L5
Canada, Quebec Quebec, Canada, G1G 3Y8
United States, California Long Beach, California, United States, 90806
United States, California Los Angeles, California, United States, 90025
United States, Florida Miami, Florida, United States, 33173
United States, Florida Sweetwater, Florida, United States, 33172
United States, Florida Tampa, Florida, United States, 33607
United States, Ohio Columbus, Ohio, United States, 43215
United States, Texas BRYAN, Texas, United States, 77802
United States, Texas Houston, Texas, United States, 77004
United States, Texas San Antonio, Texas, United States, 78213